Skip to main content

Table 4 Clinicopathologic characteristics of eight patients with LRR in the patient cohort treated with endocrine therapy and no chemotherapy

From: Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up

Patients #1 #2 #3 #4 #5 #6 #7 #8
Family history of breast cancer No Yes Yes Yes Yes Yes No No
BRCA mutations Negative Negative Negative Negative Negative Not tested Not tested Not tested
Tumor histotype IDC, Grade 2 IDC, Grade 2 IDC, Grade 1 IDC, Grade 2 ILC, not graded IDC, Grade 1 IDC, Grade 2 IDC, Grade 2
Tumor size (cm) 0.7 2.2 1.5 0.7 2.1 1.3 2 3.5
Multifocality Yes Yes Yes No No No No No
LVI No No No Yes No No Yes Yes
ER IHC (%) 100 80 90 98 98 100 95 98
PR IHC (%) 100 70 90 20 10 70 40 98
RS 0 14 7 16 14 4 17 12
 ESR1 expression 11.2 10.4 9.8 9.8 10.2 12.1 11.5 11.8
 PgR expression >10 8.8 8.7 5.8 6.6 9.1 6.3 >10
Surgery TM TM TM BCS BCS BCS BCS BCS
Radiation therapy No No No Yes Yes No Yes No
Time to LRR (months) 42 65 29 50 37 41 24 46
Site of LRR Chest wall Internal mammary node Chest wall Ipsilateral breast Ipsilateral breast Ipsilateral breast Ipsilateral breast Ipsilateral breast
  1. BCS breast conserving surgery, ER estrogen receptor, ESR1 ER gene, IDC invasive ductal carcinoma, IHC immunohistochemistry, ILC invasive lobular carcinoma, LRR locoregional recurrence, LVI lymphovascular invasion, PR progesterone receptor, PgR PR gene, RS recurrence score, TM total mastectomy